PIK3CA encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), an enzyme that converts the membrane lipid PIP2 into PIP3, thereby activating signaling cascades such as the AKT-mTOR pathway that promote cell survival, proliferation, growth, and motility. It is among the most commonly mutated genes in cancer, and aberrant activation of PI3K signaling is a driving event in tumor development, with the gene implicated in cancers including cervical cancer. Because this pathway is central to tumor growth, it is a major target of cancer therapies, although drug-induced pathway activation can also contribute to treatment resistance.

PIK3CA is a well-established cancer driver whose activating mutations promote tumor growth and are central to cancer therapy decisions. Although p.Pro449Leu falls within the gene's kinase domain, it remains a VUS because no variant-specific functional, segregation, or recurrence evidence confirms an effect - the only functional data concern a different substitution at the same residue.